Is Sunshine Biopharma, Inc. overvalued or undervalued?

As of 9 February 2023, the valuation grade for Sunshine Biopharma, Inc. has moved from does not qualify to risky, indicating increased caution regarding its financial health. The company appears to be overvalued given its significant losses and negative return metrics. Key ratios include a Price to Book Value of 0.30, an EV to EBIT of 0.18, and an EV to EBITDA of 0.19, all of which suggest that the market is not valuing the company favorably compared to its peers.
In comparison to its peers, Sunshine Biopharma's valuation metrics are less favorable; for instance, Cyclerion Therapeutics, Inc. has an EV to EBITDA of -1.2082, while Blue Water Biotech, Inc. stands at -1.3625. The company's stock has significantly underperformed against the S&P 500, with a year-to-date return of -51.0% compared to the S&P 500's 12.22%, reinforcing the notion that Sunshine Biopharma is overvalued in the current market context.